| 2.47 -0.135 (-5.18%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.19 | 1-year : | 3.48 |
| Resists | First : | 2.73 | Second : | 2.98 |
| Pivot price | 2.62  |
|||
| Supports | First : | 2.34 | Second : | 1.95 |
| MAs | MA(5) : | 2.63 |
MA(20) : | 2.59 |
| MA(100) : | 1.92  |
MA(250) : | 2.17 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 35.1 |
D(3) : | 51.4 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 3.86 | Low : | 0.95 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CDXS ] has closed above bottom band by 14.1%. Bollinger Bands are 27.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.69 - 2.71 | 2.71 - 2.72 |
| Low: | 2.4 - 2.41 | 2.41 - 2.42 |
| Close: | 2.45 - 2.47 | 2.47 - 2.49 |
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Sun, 07 Jun 2026
Why Did CDXS Stock Jump 7% Today? - Stocktwits
Mon, 11 May 2026
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results - simplywall.st
Mon, 11 May 2026
Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58 - Yahoo Finance
Thu, 07 May 2026
Codexis: Q1 Earnings Snapshot - KTVB
Thu, 07 May 2026
Codexis (NASDAQ: CDXS) Q1 2026 revenue hits $15.2M as net loss shrinks - Stock Titan
Thu, 12 Mar 2026
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform (NASDAQ:CDXS) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 91 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 7.4 (%) |
| Held by Institutions | 74.3 (%) |
| Shares Short | 3,700 (K) |
| Shares Short P.Month | 6,280 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.47 |
| Profit Margin | -41 % |
| Operating Margin | -52.8 % |
| Return on Assets (ttm) | -12.6 % |
| Return on Equity (ttm) | -69 % |
| Qtrly Rev. Growth | 102 % |
| Gross Profit (p.s.) | 0.2 |
| Sales Per Share | 0.85 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -7.06 |
| PEG Ratio | 13.5 |
| Price to Book value | 5.14 |
| Price to Sales | 2.87 |
| Price to Cash Flow | -11.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|